Amos is a graduate fellow at the International Livestock Research Institute in Nairobi, Kenya, and intends to pursue a PhD in immunology and vaccinology.
This workshop brought together groups interested in sporozoite production for the parasite Theileria parva, which causes the disease East Coast fever.
Sixty-eight IVVN members joined a virtual workshop to hear about the outcomes from the IVVN-funded pump-priming project 'Efficacy testing of novel immersion and oral vaccines for Aeromonas hydrophila in tilapia and Vietnamese catfish'.
A new concise and authoritative reference compiled by the FAO, with contributions from international leading experts, covers a wide range of topics related to veterinary vaccine development, production and use.
With emerging disease at the forefront of global health priorities as never before, The Bloomsbury SET is developing new solutions to combat infectious disease and antimicrobial resistance.
The UK biotech startup is working on designing variant-proof vaccines against ASFV and PRRSV, based on their deep learning data-driven platform.
Dr Matthew Edmans, a postdoctoral researcher at the University of Oxford, writes about his recent publication with other IVVN members that identified MAIT cells in cattle and characterised their response to bacterial infections.
A blog post from the IDRC's Livestock Vaccine Innovation Fund on the mentorship opportunity gap for women from LMICs and the opportunities offered by the IVVN Fellowship Programme.
Results from the 2020 survey of IVVN members.
Animal African trypanosomiasis is one of the most significant infectious disease threats to livestock across sub-Saharan Africa, and is also important across Asia and South America. This workshop brought together representatives to discuss recent advances and how to facilitate vaccination research.
A vaccine is the most effective and safest way of ending the COVID-19 pandemic. But which vaccine types are being tested and how far have the projects progressed?
We spoke with Dr Volker Gerdts, Director and CEO of VIDO-InterVac, about his organisation’s work on developing and testing a subunit vaccine against SARS-CoV-2.